Tempus Unveils New Whole-Genome Sequencing Assay
The whole-genome sequencing assay enhances precision medicine by identifying relevant genetic alterations in hematological malignancies.
Read MorePosted by Andy Lundin | Jan 15, 2025 | Hematology & Serology, Molecular Diagnostics |
The whole-genome sequencing assay enhances precision medicine by identifying relevant genetic alterations in hematological malignancies.
Read MorePosted by Andy Lundin | Nov 19, 2024 | Point-of-Care, Sample Storage & Management |
Fluxergy is collaborating with NIAID to enhance molecular testing and sample preparation on its innovative platform.
Read MorePosted by Andy Lundin | Nov 13, 2024 | Mass Spectrometry Reagents & Test Kits, Point-of-Care |
This collaboration aims to advance a smartphone-based hemoglobin test for accessible diagnostics of anemia and other health conditions.
Read MorePosted by Andy Lundin | Oct 28, 2024 | Sepsis |
The $5 million contract will help develop a diagnostic system that delivers fast CBC results and improves early detection for sepsis.
Read MorePosted by Andy Lundin | Oct 8, 2024 | Leukemia, Sequencing Systems |
The next-generation sequencing assay delivers rapid and comprehensive genetic profiling for AML patients, guiding precise treatment decisions.
Read More